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Inherited predisposition to breast cancer is known to be caused by
loss-of-function mutations in BRCA1, BRCA2, PALB2, CHEK2, and
other genes involved in DNA repair. However, most families se-
verely affected by breast cancer do not harbor mutations in any of
these genes. In Finland, founder mutations have been observed in
each of these genes, suggesting that the Finnish population may
be an excellent resource for the identification of other such genes. To
this end,we carriedout exome sequencingof constitutional genomic
DNA from 24 breast cancer patients from 11 Finnish breast cancer
families. From all rare damaging variants, 22 variants in 21 DNA re-
pair geneswere genotyped in 3,166 breast cancer patients, 569 ovar-
ian cancer patients, and 2,090 controls, all from the Helsinki or
Tampere regions of Finland. In Fanconi anemia complementation
gene M (FANCM), nonsense mutation c.5101C>T (p.Q1701X) was
significantly more frequent among breast cancer patients than
among controls [odds ratio (OR) = 1.86, 95% CI = 1.26–2.75; P =
0.0018], with particular enrichment among patients with triple-
negative breast cancer (TNBC; OR = 3.56, 95% CI = 1.81–6.98, P =
0.0002). In the Helsinki and Tampere regions, respectively, carrier
frequencies of FANCM p.Q1701X were 2.9% and 4.0% of breast
cancer patients, 5.6% and 6.6% of TNBC patients, 2.2% of ovarian
cancer patients (from Helsinki), and 1.4% and 2.5% of controls.
These findings identify FANCM as a breast cancer susceptibility gene,
mutations in which confer a particularly strong predisposition
for TNBC.
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Breast cancer is the most common cancer affecting womenworldwide. It is also the principal cause of death from cancer
among women globally, accounting for 14% of all cancer deaths
(1). The etiology of breast cancer is multifactorial, and the risk
depends on various factors like age, family history, and repro-
ductive, hormonal, or dietary factors. The majority of breast can-
cers are sporadic, but approximately 15% of cases show familial
aggregation (2, 3). Since the identification of the first breast and
ovarian cancer susceptibility genes breast cancer 1 and 2 (BRCA1
and BRCA2, respectively) by linkage analysis and positional
cloning, several breast cancer susceptibility genes and alleles with
different levels of risk and prevalence in the population have been
recognized. BRCA1 and BRCA2mutation carriers have more than
10-fold increased risk of breast cancer compared with women in
the general population, andmutations inTP53, PTEN, STK11, and
CDH1 have also been associated with a high lifetime risk of breast
cancer in the context of rare inherited cancer syndromes (4). In
addition, rare variants in genes such as checkpoint kinase 2
(CHEK2), ataxia telangiectasia mutated (ATM), and BRCA1
interacting helicaseBRIP1, that confer a two- to fourfold increased
risk, and in partner and localizer of BRCA2 (PALB2), with even
higher risk estimates, have been found with candidate gene
approaches (5, 6), and an increasing number of common low-risk
loci with modest odds ratios (ORs; as much as 1.26-fold increased
risk for heterozygous carriers) have been identified by genome-
wide association studies (7).
However, the major portion of hereditary breast cancer still
remains unexplained, and many susceptibility loci are yet to be
found. Exome sequencing combined with genotyping of the
identified variants in case-control analysis is an effective method
to recognize novel risk alleles, based on the assumption that
disease-causing variants are rare and often accumulate in the
protein-coding areas of the genome (8–10).
Since the discovery that proteins encoded by the BRCA1 and
BRCA2 breast/ovarian cancer susceptibility genes are directly
involved in homologous recombination repair of DNA double-
strand breaks, it has been evident that other genes involved in
DNA repair are attractive breast cancer susceptibility candidates
(4). Biallelic mutations in ATM gene cause rare ataxia telangiec-
tasia disease and are associated with an increased risk for breast
cancer as a result of improper DNA damage response (11).
Fanconi anemia (FA) is a rare genetic disorder caused by biallelic
mutations in FA genes that also participate in DNA repair. At
least 15 FA genes have been identified (12). Patients with het-
erozygous mutations in certain FA genes have an elevated risk for
various cancers, and monoallelic mutations in at least four of
these genes [BRCA2, BRIP1, PALB2, and RAD51 paralog C
(RAD51C)] are associated with an increased risk of breast or
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ovarian cancer (12, 13). Recurrent founder mutations in several
cancer susceptibility genes, including the BRCA2, PALB2, and
RAD51C FA genes, have been identified in the Finnish population
(14–16). The PALB2 and RAD51C founder mutations have been
detected at 2% frequency in Finnish breast or ovarian cancer
families (15–17), whereas, in other populations, mutations in these
genes are rare and often unique for each family. Founder effects
in the isolated populations such as Finland or Iceland may enrich
certain mutations and thus explain a significant proportion of all
mutations in certain genes (18, 19). This provides an advantage in
the search for novel susceptibility genes and alleles.
In this study, we used exome sequencing to uncover previously
unidentified recurrent breast or ovarian cancer predisposing
variants in the Finnish population with a focus on DNA repair
genes. Selected variants were further genotyped in a large case-
control sample set. Our investigation revealed an association of
a nonsense mutation (rs147021911) in an FA complementation
gene, FANCM, with breast cancer, especially with triple-negative
(TN) breast cancer (TNBC).
Results
Exome Sequencing and Identification of Candidate Variants. Exome
sequencing was performed on germ-line DNA samples of 24
BRCA1/2-negative patients from 11 breast cancer families. All
families had at least three breast or ovarian cancer patients among
first- or second-degree relatives. We identified a total of 80,918
variants in 80,867 nonsynonymous positions, with a mean read
coverage of 101. More than 91% of the captured exome target
region was covered by at least 10 reads in all samples.
Several filtering steps were applied to the exome sequencing
data to prioritize variants for further validation and follow-up
studies (Fig. S1). Variants with mean coverage <15 and common
variants (minor allele frequency ≥ 1%) in the 1000 Genomes
Project (20) or Exome Variant Server data [National Heart, Lung,
and Blood Institute (NHLBI) Grand Opportunity (GO) Exome
Sequencing Project; evs.gs.washington.edu/EVS/; January 2013]
were excluded. Population-matched exome-sequenced controls
(n = 144) allowed exclusion of variants and indels based on the
frequency in the Finnish population. Annovar (21) was used for
annotation of the variants. Protein truncating alterations including
nonsense variations, frame-shift insertions/deletions, and splice-
site variants were manually examined with Integrative Genomics
Viewer (22) and RikuRator, an in-house visualization tool (cre-
ated by Riku Katainen, University of Helsinki) to remove possible
artifacts. Only variants predicted to be pathogenic were included
in the study.
Given that the majority of the known breast cancer pre-
disposition genes are involved in DNA double-strand break re-
pair, we concentrated on variants identified in genes defined as
DNA repair genes in the Gene Ontology project (via AmiGO
browser) (23). A total of 22 variants were identified in 21 DNA
repair genes, including 20 single-nucleotide variants (SNVs) and
two indels (endonucleaseNEIL1 c.314dupC and protein ligase and
helicase SHPRH c.3577_3580delCTTA; Table S1). Both indels
were confirmed by Sanger sequencing. Three variants showed some
evidence of cosegregation with cancer in families. Specifically, an
SHPRH deletion, a DNA glycosylaseMPG splicing mutation, and
an ATPase RUVBL1 missense variant were detected in both
exome-sequenced members of the respective families. In addition,
a single PAX interacting protein 1 (PAXIP1) missense variant was
detected in two unrelated cases, raising the possibility that the
variant is present at an increased frequency in Finnish breast
cancer families. The rest of the variants were observed in only
one case.
Genotyping Population-Matched Cases and Controls. Associations
between the selected variants and breast and ovarian cancer
were evaluated in further studies. In phase I, the 22 variants were
genotyped in a pilot set of 524 familial BRCA1/2-negative breast
cancer patients from the Helsinki region of Finland to determine
whether the variants were recurrent in Finnish families and thus
relevant for genotyping in a larger set of samples. All patients
had strong family history of breast cancer, with at least three
breast or ovarian cancer patients in the family among first- or
second-degree relatives (411 families with breast cancer only and
113 families with both breast and ovarian cancer). Genotyping of
the SNVs was performed with Sequenom MassARRAY system
using iPLEX Gold assays, genotyping of PAXIP1 c.803C>T and
NEIL1 c.314dupC was performed with TaqMan real-time PCR,
and genotyping of SHPRH c.3577_3580delCTTA was conducted
by Sanger sequencing. After phase I, 13 SNVs and the SHPRH
c.3577_3580delCTTA deletion were excluded from further anal-
ysis as no additional mutation carriers were found (Table S1). The
Fanconi anemia complementation group A (FANCA) c.1682C>T
missense variant was discarded because the iPLEX genotyping
assay did not produce a reliable result.
In phase II, BRCA1 associated RING domain 1 (BARD1)
c.2282G>A and PAXIP1 c.803C>T missense variants and the
NEIL1 c.314dupC variant, which were not included in the
iPLEX assay, were genotyped with TaqMan real-time PCR in
population matched healthy female controls (n = 552) to define
the mutation frequency in the general Finnish population. The
frequencies of the missense variants BARD1 c.2282G>A (1.8%
for controls, 2.2% for cases) and PAXIP1 c.803C>T (0.5% for
controls, 1.2% for cases) were similar to the phase I familial
cases or too rare for final statistical assessment in our datasets,
and thus these variants were excluded from further analysis
(Table S2). The NEIL1 c.314dupC mutation was present in one
control and was selected for further genotyping in phase III. The
remaining five SNVs were genotyped simultaneously in phase II
and phase III samples by Sequenom MassARRAY.
In phase III, five SNVs were genotyped by Sequenom
MassARRAY on an additional 233 familial BRCA1/2-negative
breast cancer patients, 1,730 unselected breast cancer cases
from the Helsinki region, and 679 unselected breast cancer
patients (including 257 familial cases) from the Tampere region
of southwestern Finland. For population controls, a total of
1,274 healthy females from Helsinki and 816 from the Tampere
region were genotyped. The SNVs were also genotyped in
a series of unselected ovarian cancer patients (n = 569) from
the Helsinki region. The success rates for the assays varied be-
tween 97.9% and 100% after excluding samples with no accept-
able results or low success rates. NEIL1 c.314dupC was genotyped
with TaqMan real-time PCR in the familial and unselected breast
cancer cases and population controls.
FANCA c.4228T>G was not observed in any of the phase
III genotyped patients, RUVBL1 c.950G>A was detected in
one additional breast and one ovarian cancer sample, and
MPG c.40–1G>T, SLX4 structure-specific endonuclease sub-
unit (SLX4) c.2484G>C, FANCM c.5101C>T, and NEIL1
c.314dupC were detected in 10 or more additional samples
(Table S2).
FANCM c.5101C>T Associates with Breast Cancer Risk. After com-
bining results from the three phases of genotyping in two in-
dependent series of breast cancer cases and controls, a significant
association with breast cancer was found for FANCM c.5101C>T
nonsense mutation (14:45658326C>T, rs147021911, p.Q1701X).
Approximately twofold increased mutation frequency was found
among breast cancer cases (2.9%) compared with controls (1.4%)
in the Helsinki sample set (OR = 2.06, 95% CI = 1.22–3.47; P =
0.006; Table 1). To identify the patient characteristics associated
with the highest risk of disease, we divided the genotyped patients
into subgroups according to family history of breast or ovarian
cancer, estrogen receptor (ER) status, and TN subtype, i.e., ER-,
progesterone receptor-, and HER2-negative tumors. The associ-
ation was consistent among familial cases (OR = 2.21, 95% CI =
1.24–3.94; P = 0.006) and among unselected cases (OR = 2.01,
95% CI = 1.16–3.47; P = 0.011), with 3.2% carrier frequency
among patients with strong family history of breast cancer and
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2.9% among patients with only one affected first-degree relative.
The frequencies were similar in breast cancer-only families
(3.2%) and families with both breast and ovarian cancer (3.5%).
Among the unselected ovarian cancer patients, a consistent but
nonsignificant result was seen, with 2.2% mutation carrier fre-
quency (OR = 1.56, 95% CI = 0.75–3.26; P = 0.235). When
studied by subtype of breast cancer, the risk was somewhat
higher in the ER-negative subgroup (OR = 2.38, 95% CI = 1.17–
4.83; P = 0.013) than in the ER-positive subgroup (OR = 1.83,
95% CI = 1.05–3.17; P = 0.029), and the highest risk and most
significant association was found with TN breast cancer (OR =
4.13, 95% CI = 1.76–9.67; P = 0.0004). Among the 143 TN cases
in the Helsinki region, 24 had family history of breast cancer and
two of them were mutation carriers (8.3%, OR = 6.33, 95% CI =
1.38–28.95; P = 0.047 vs. controls). Among the unselected TN
patients, FANCM c.5101C>T associated with breast cancer (P =
0.0001; OR = 4.92, 95% CI = 2.01–12.07).
Consistent results were observed in the independent Tampere
breast cancer case-control series (Table 1), with the highest OR
among the TN cases (OR = 2.77, 95% CI = 0.92–8.37; P =
0.0806). Meta-analyses of the two series, combining the estimates
from the Helsinki and Tampere datasets, confirmed the associa-
tion among all of the genotyped breast cancer cases (N = 3,079;
OR = 1.86, 95% CI = 1.26–2.75; P = 0.0018), among familial cases
(OR = 2.11, 95% CI = 1.34–3.32; P = 0.0012), and the highest risk
in the TN subgroup (OR = 3.56, 95% CI = 1.81–6.98; P = 0.0002).
P < 0.0023 was considered significant after Bonferroni correction
for the number of variants tested, and the P values remained sig-
nificant after the multiple testing correction. In the meta-analysis,
there was borderline-significant heterogeneity in the risks between
ER-positive and TN breast cancer (Phet = 0.059), suggesting an in-
creased risk especially for TNBC.
Altogether, 96 FANCM c.5101C>T mutation carriers were
found among the breast cancer cases. In the Helsinki series, 17
carriers had a strong family history of breast cancer, 16 had one
first-degree relative affected with breast or ovarian cancer, and 36
were sporadic breast cancer patients who did not fulfill the family
history criteria. From the Tampere region, 12 familial and 15
sporadic cases carried the FANCM c.5101C>Tmutation. The mean
age of the FANCM c.5101C>T mutation carriers at breast cancer
diagnosis was 55.2 y, whereas the mean age of the noncarriers was
56.4 y (P = 0.416). In both the Helsinki and Tampere series, the
mutation was also detected in 38 female population controls.
Among the 548 unselected ovarian cancer cases, 12 carried the
mutation. Age at ovarian cancer diagnosis was available for 11
mutation carriers and 525 noncarriers. The mean age was 53.7 y
for the carriers and 55.4 y for the noncarriers (P = 0.569). Six of
the tumors were of serous histology, two were mucinous, two were
other subtypes, and histology was unknown for two.
To study the FANCM nonsense mutation in another strong
founder population, we genotyped 965 unselected breast cancer
patients, including 92 familial cases from Iceland, but no FANCM
c.5101C>T mutations were detected in this sample set, suggesting
the mutation is absent or extremely rare in Iceland.
To study the familial segregation of FANCM c.5101C>T, 45
individuals from eight mutation carrier families were genotyped.
Among 11 female relatives with breast cancer, five carried the
FANCM c.5101C>T mutation. Notably, all of these mutation
carriers were first-degree relatives of the index patients, whereas all
but one of the breast cancer cases with the WT genotype were
more distant relatives. Among 16 healthy female relatives,
seven carried the mutation (aged between 33 and 80 y). Most of
the families showed incomplete segregation of the mutation,
but, in one of the carrier families, all three sisters affected with
breast cancer were mutation carriers (Fig. 1). Among eight
genotyped relatives affected with other types of cancer, one
man diagnosed with prostate cancer at the age of 48 y and one
woman affected with an undefined cancer were mutation-positive.
Table 1. Frequency of the FANCM c.5101C>T nonsense mutation among unselected and
familial breast cancer patients, unselected ovarian cancer patients, and population controls
Study cohort N CC (%) CT (%) OR 95% CI P value
Helsinki
Controls 1,271 1,253 (98.6) 18 (1.4) — — —
All BC 2,405 2,336 (97.1) 69 (2.9) 2.06 1.22–3.47 0.0059
Familial BC 1,074 1,041 (96.9) 33 (3.1) 2.21 1.24–3.94 0.0061
≥3 affected 524 507 (96.8) 17 (3.2) 2.33 1.19–4.57 0.0109
BC only 410 397 (96.8) 13 (3.2) 2.28 1.11–4.69 0.0217
BC + OC 114 110 (96.5) 4 (3.5) 2.53 0.84–7.61 0.1003
2 affected 550 534 (97.1) 16 (2.9) 2.09 1.06–4.12 0.0307
Unselected BC 1,713 1,665 (97.2) 48 (2.8) 2.01 1.16–3.47 0.0109
ER+ 1,799 1,753 (97.4) 46 (2.6) 1.83 1.05–3.17 0.0293
ER− 423 409 (96.7) 14 (3.3) 2.38 1.17–4.83 0.0132
TN 143 135 (94.4) 8 (5.6) 4.13 1.76–9.67 0.0004
Unselected OC 548 536 (97.8) 12 (2.2) 1.56 0.75–3.26 0.2346
Tampere
Controls 809 789 (97.5) 20 (2.5) — — —
All BC 674 647 (96.0) 27 (4.0) 1.65 0.91–2.96 0.0932
Familial BC 253 241 (95.3) 12 (4.7) 1.96 0.95–4.08 0.0651
ER+ 509 491 (96.5) 18 (3.5) 1.45 0.76–2.76 0.2610
ER− 124 117 (94.4) 7 (5.6) 2.36 0.98–5.70 0.0497
TN 61 57 (93.4) 4 (6.6) 2.77 0.92–8.37 0.0806
Meta-analysis
All BC 3,079 — — 1.86 1.26–2.75 0.0018
Familial 1,327 — — 2.11 1.34–3.32 0.0012
ER+ 2,308 — — 1.66 1.09–2.52 0.0182
ER− 547 — — 2.37 1.37–4.12 0.0021
TN 204 — — 3.56 1.81–6.98 0.0002
BC, breast cancer; OC, ovarian cancer; ≥3 affected, families with ≥3 BC or OC cases among first- or second-
degree relatives; 2 affected, families with two first-degree relatives with BC or OC. Two-sided P values are
calculated with Pearson χ2 or Fisher exact test if the expected number of cell count is ≤5.
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Among the relatives without available DNA samples, several
other cancer types in addition to breast and ovarian cancer were
also present, including prostate, pancreatic, skin, lung, colorectal,
bone marrow, liver, and kidney cancer.
To investigate whether the FANCM c.5101C>T causes non-
sense-mediated mRNA decay, we performed allele-specific quan-
titative real time-PCR for WT and c.5101C>T mutant FANCM
alleles. Equal proportions of the WT and mutant allele were
detected in RNA from a c.5101C>T carrier, whereas only the WT
allele was detected in controls (Fig. S2). These results indicate
that the c.5101C>T allele was not subject to nonsense-mediated
mRNA decay.
The other studied DNA repair gene variants did not show
a statistically significant difference in frequencies between cases
and controls (SI Results and Discussion and Table S2), although
FANCA c.4228T>G was detected in two breast cancer cases and
RUVBL1c.950G>A in three breast cancer cases and one ovarian
cancer case, but not in any of the controls.
Discussion
We used exome sequencing of breast cancer families in the ge-
netically homogenous Finnish population to identify recurrent
alleles associated with cancer risk in previously unidentified
breast and ovarian cancer susceptibility genes. By concentrating on
DNA repair genes, 22 variants from our exome sequencing data
were selected for further evaluation in large datasets of familial
and unselected breast cancer patients and population controls from
two independent case-control series in different regions of Finland
as well as in a series of unselected ovarian cancer cases.
We found a c.5101C>T (rs147021911) variant encoding a
premature FANCM stop codon (p.Q1701X) in 96 Finnish
breast cancer patients and 12 Finnish ovarian cancer patients.
Although FANCM c.5101C>T is very rare in the 1000 Genomes
Project European population (minor allele frequency = 0.005), it
is observed at a higher frequency in the Finnish population, and
was here found at a twofold increased frequency among familial
and unselected breast cancer cases from two studies relative to
population controls. In the FANCM c.5101C>T mutation carrier
families, additional genotyping of the available affected relatives
did not demonstrate distinct segregation of the mutation. In-
stead, the mutation had incomplete segregation with the disease,
consistent with FANCM c.5101C>T being a moderate-risk allele,
which alone may not explain the clustering of the disease in the
pedigrees in which, presumably, other unknown predisposition
alleles may also segregate.
When considering breast tumor histopathology, FANCM
c.5101C>T was observed more frequently in ER-negative than
ER-positive breast cancer patients, and the strongest association
was observed in TNBC patients, with ORs ranging from 2.77 to
4.13. This finding is consistent with enrichment for germ-line var-
iants in DNA repair genes among TNBC cases. Specifically, muta-
tions in the breast cancer predisposing genes BRCA1 and BRCA2
have been observed in as many as 15% of TNBC cases, and 70% of
BRCA1-associated breast tumors exhibit TN characteristics. In ad-
dition, three known TNBC-specific low-risk loci (TERT,MERIT40,
and MDM4) contain genes that participate in DNA repair and
maintenance of genome stability (24, 25). Our findings suggest that
FANCM is a breast cancer susceptibility gene, mutations in which
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confer a particularly strong predisposition for TNBC. The im-
proved understanding of the etiology of the TN subtype of breast
cancer may lead to identification of new targeted treatments or
development of therapeutic agents for this form of breast cancer.
Conversely, in the unselected ovarian cancer series, unambiguous
association was not detected (OR = 1.56, 95% CI = 0.75–3.26; P =
0.235), although the OR and 95% CIs were consistent with an in-
creased ovarian cancer risk. A larger sample set is needed for fur-
ther investigation of the association of FANCM c.5101C>T
mutation with ovarian cancer risk and to uncover potential asso-
ciations with specific ovarian cancer subtypes.
We also genotyped the FANCM c.5101C>T nonsense muta-
tion in 965 breast cancer patients from Iceland. The mutation
was not found in this sample set and therefore may be very rare
in the genetically isolated Icelandic population. However, other
pathogenic, possibly population-specific FANCM mutations may
confer an increased risk of breast cancer in this population.
Furthermore, other cancer-predisposing FANCM mutations may
also exist in the Finnish population, and further studies to evaluate
the whole contribution of FANCM are warranted.
In the Finnish population, the CHEK2 moderate-risk allele
c.1100delC is observed at a similar population-control frequency
as the FANCM mutation in the Helsinki dataset, but with a
higher frequency among familial breast cancer patients (5.5%),
with approximately fourfold elevated risk (26). This is comparable
to the FANCM mutation among the TN patients and specifically
the TNBC patients with family history of breast cancer. CHEK2 is
thought to be a risk modifier gene with multiplicative effects with
other susceptibility alleles in breast cancer families. Thus, the breast
cancer risk estimates for c.1100delC mutation carriers are influ-
enced by family history. The lifetime risk of breast cancer for
carriers ofCHEK2 truncatingmutations is estimated to range from
20% for a woman with no affected relative to 44% for a woman with
a first- and a second-degree relative affected (27). Interestingly,
the CHEK2 missense-mutation I157T is a lower-risk allele with ap-
proximately 1.5-fold elevated cancer risk among unselected and
familial cases, whereas it associates specifically with approximately
fourfold increased risk of lobular breast cancer (28).
FANCM is the most conserved protein within the FA pathway
(29). The main function of this pathway is to activate a DNA
damage response when encountering stalled replication forks in
response to DNA damage. FANCM has a translocase and en-
donuclease activity, and its functions are essential for promoting
branch migration of Holliday junctions and DNA repair struc-
tures at replication forks. It can suppress spontaneous sister
chromatid exchanges and maintain chromosomal stability, sug-
gesting a tumor-suppressor role in cells (29–31). The c.5101C>T
variant results in truncation of the FANCM protein and would
be predicted to cause nonsense-mediated mRNA decay. However,
no nonsense-mediated mRNA decay of the c.5101C>T allele was
detected, suggesting that the continued expression of the mutant
allele and almost full-length protein levelsmay in part account for the
moderate influence of the variant on risk. The FANCM c.5101C>T
mutation is located at exon 20 causing a premature stop codon at
Gln1701, which causes the loss of two protein domains (ERCC4 and
RuvA domain 2-like) in the C terminus (Fig. 2). This may affect the
DNA binding abilities of the FANCM protein during stalled repli-
cation fork processing andmonoubiquitination of the repair complex
proteins (32). The ERRC4 domain can contribute to DNA binding
and it also has nuclease activity; however a full-length FANCM
protein has stronger DNA binding abilities than its C-terminal do-
main. The other C-terminal domain RuvA domain 2-like including
HtH motif strengthens the ability of FANCM to bind especially to
Holliday junctions and participate in DNA repair. The two translo-
case domains in FANCM protein are located in the N terminus. It is
likely that all these protein domains in FANCM act sequentially in
replication fork processing (31, 33, 34) (Interpro; www.ebi.ac.uk/
interpro/protein/Q8IYD8; July 2014).
Our findings are consistent with previous studies showing that
fancm-deficient mice have increased cancer incidence (33). In ad-
dition, homozygous missense mutations in FANCM (c.5164C>T,
p.P1722S) have been found in breast tumors (35), and four dif-
ferent FANCM SNPs have been associated with osteosarcoma risk
(36). Also, in colorectal cancer (CRC) patients, an FANCM non-
sense mutation (c.5791C>T, p.Arg1931Ter) has been identified
(37), but further studies are needed to clarify the potential role of
FANCM in CRC susceptibility. However, only one FA patient has
been found to carry truncating FANCM mutation and this in-
dividual also carries biallelicmutations in theFANCA gene (33, 38).
Furthermore, homozygous carriers of FANCM loss-of-function
mutations c.5101C>T and c.5791C>T observed in the Finnish
population do not show symptoms of FA (39). Thus, FANCM
may have tumor suppressor activity, but, despite its role in the
FA pathway, it may not contribute to FA.
Conclusions
In summary, the FANCM c.5101C>T nonsense mutation associates
with breast cancer risk in the Finnish population. This is consistent
with recent murine studies that indicate FANCM as a tumor-sup-
pressor gene and increased cancer incidence in fancm-deficient
mice. The highestmutation frequency and strongest associationwith
breast cancer risk was observed among TNBC patients, further
implicating DNA repair in the etiology of this aggressive form of
breast cancer. Further studies in different populations, especially in
familial cases, are essential for more precise estimation of breast
cancer risks associated with this mutation. The discovery of variants
such as FANCM c.5101C>T is essential for individualized breast
cancer risk assessment and early diagnosis for breast cancer families.
Materials and Methods
Ethics Approval. This study was approved by Helsinki University Central Hospital
Ethics Committee (reference no. 272/13/03/03/2012), the Icelandic Data Protection
Authority (reference no. 20010505239 and later amendments), and the National
Bioethic Committee (reference no. 99/051-B1/B2 and later amendments).
Samples.Weselected24BRCA1/2-negativebreast cancerpatients from11 Finnish
breast cancer families (minimum of three breast or ovarian cancers in first- or
second-degree relatives) for exome sequencing.We included two cases fromnine
families and three from two families. Selected exome variantswere genotyped in
additional breast and ovarian cancer patients and population controls in phases
I–III, totaling 3,166 breast cancer cases and 2,090 healthy female population
controls. Phase I consistedof 524BRCA1/2-negative familial breast cancer patients
from the Helsinki region of Finland. Phase II consisted of 552 population controls.
Phase III consisted of 1,730 unselected breast cancer patients, 233 additional fa-
milial BRCA1/2-negative patients, and a total of 1,274 population controls (in-
cluding the 552 controls from phase II) from the Helsinki region, as well as 679
unselected breast cancer patients (including 257 familial cases) and 816 pop-
ulation controls from the Tampere region of Finland. In addition, the selected
substitutions were genotyped in an unselected series of ovarian cancer patients
(n= 569) from theHelsinki region, and the identified FANCM nonsensemutation
was also genotyped in an unselected series of Icelandic breast cancer patients,
including 92 familial and 873 sporadic cases. The studied cohorts are described in
SI Materials and Methods.
Exome Sequencing. Exome sequencing and variant calling was performed at
Genome Quebec Innovation Centre. The Agilent SureSelect Human All Exon
50-Mb kit was used to capture the exomic regions from 3 μg of genomic DNA.
The sequencing was performed on Illumina HiSeq2000 sequencer with
100-bp paired-end reads. Details of the exome data analysis are given in SI
Materials and Methods.
cDNA 5´
EXON 3222120291817161514131211101987654321
Helicase ATP-binding
Helicase C-terminal ERCC4 domain
RuvA domain 2-like
Ser724Ter Exon 15 del   Gln1701Ter
3´
Fig. 2. Drawing of FANCM indicating protein domains, the position of the
c.5101C>T nonsense mutation, and positions of the mutations found from
a single FA patient carrying FANCM and FANCA defects. Mutations and
protein domains are mapped to the corresponding exons of FANCM.
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Variant Filtering. We used several filtering criteria to select variants from
exome sequencing data for further genotyping. Variants with mean read
coverage less than 15 were excluded. Filtering of common variants (≥1%
frequency) was performed using the 1000 Genomes Project (20), Exome
Variant Server (NHLBI GO Exome Sequencing Project; evs.gs.washington.
edu/EVS/; January 2013), and exome data from 144 Finnish noncancer control
samples. The candidate genes and variants were annotated by using AmiGO
(23) and Annovar (21), and genes participating in DNA repair were selected
for further analysis. Only variants predicted to change protein sequence
(frame-shift deletions and insertions, splicing alterations, and missense and
nonsense SNVs) were considered. Of the missense variants, only those pre-
dicted to be pathogenic were included. After these filtering steps, we
manually examined the remaining variants to visualize and verify their
structure and position, and also to remove possible sequencing artifacts,
with the use of the analysis and visualization program Interactive Genomics
Viewer (22) and in-house visualization tool Rikurator (Riku Katainen, Uni-
versity of Helsinki). Indels that passed the filtering steps were confirmed by
Sanger sequencing before genotyping (SI Materials and Methods).
Genotyping. Genotyping of the selected 22 variants from 21 DNA repair
genes was performed with Sequenom MassARRAY system, TaqMan real-time
PCR, or Sanger sequencing (Table S1) as described in SI Materials and Methods.
Variants detected in subsequent samples in phase I were selected for further
genotyping. Those variants passing phase I that could be included on the
Sequenom MassARRAY were simultaneously genotyped in phase II and phase
III samples. Variants that were not included on the array because of technical
reasons (BARD1 c.2282G>A, PAXIP1 c.803C>T, and NEIL1 c.314dupC) were first
genotyped with TaqMan real-time PCR in population controls in phase II, and
those that were detected frequently in controls were excluded from phase III.
The phase III genotyping for the remaining variant (NEIL1 c.314dupC) was also
executed with TaqMan real-time PCR. Additional relatives from the FANCM
c.5101C>T mutation carrier families were genotyped by Sanger sequencing
(Table S3). In addition, the FANCM mutation was also genotyped in 965 Ice-
landic breast cancer patients with TaqMan real-time PCR.
Nonsense-Mediated mRNA Decay. Quantitative allele-specific FANCM RT-PCR
was performed with RNA extracted from lymphoblastoid cells from a het-
erozygous carrier of the c.5101C>T variant and six noncarriers (SI Materials
and Methods).
Statistical Analyses. Two-sided P values were calculated by Pearson χ2 test or
Fisher exact test if the expected number of cell count was five or less. For
meta-analysis, we combined the estimates from Helsinki and Tampere with
a fixed effects model by using the inverse variance-weighted method. Meta-
analysis was performed by using R.3.0.1 environment (www.r-project.org/).
For multiple testing correction, the Bonferroni method was used, and het-
erogeneity between ER-positive and TN subgroups was determined by two-
sample z-test. The mean age of FANCM c.5101C>T mutation carriers and
noncarriers was compared with Student paired t test.
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